Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AMAG Pharmaceuticals Inc Raises FY 2013 Revenue Guidance


Wednesday, 23 Oct 2013 07:00am EDT 

AMAG Pharmaceuticals Inc increased its total revenue forecast to between $78 million and $81 million for fiscal 2013. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $79 million for fiscal 2013. 

Related Company News

Company Quote

20.71
0.31 +1.52%
22 Aug 2014